<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/apparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/apparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2018-01-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2018-01-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/apparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa/"},"url":"https://clinicaltree.github.io/posts/apparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa/"}</script><title>Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1517418000" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Jan 31, 2018 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Yazmín Aseret Ramírez-Galván MD</a> </em>, <em> <a href="">Servo Cardona-Huerta MD PhD</a> </em>, <em> <a href="">Guillermo Elizondo-Riojas MD PhD</a> </em>, <em> <a href="">Neri Alejro Álvarez-Villalobos MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2220 words"> <em>12 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>This study explored tumor behavior in patients with breast cancer during neoadjuvant chemotherapy (NAC) by sequential measurements of tumor apparent diffusion coefficient (ADC) after each chemotherapy cycle. The aim was to determine if the tumor ADC is useful to differentiate complete pathological response (cPR) from partial pathological response (pPR) during NAC.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>A total of 16 cases (in 14 patients) with diagnosis of breast cancer eligible to receive NAC were included. There were 70 magnetic resonance imaging examinations performed, 5 for each patient, during NAC cycles. Diffusion-weighted imaging was performed on a 1.5T system (b values of 0 and 700s/mm 2 ). Four ADC ratios between the five MRI examinations were obtained to assess ADC changes during NAC. Absence of invasive breast cancer at surgical specimens (Miller-Payne 5) was considered as cPR and was used as reference for ADC cutoff ratios.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>In this study, we were able to differentiate between cPR and pPR, after two cycles of NAC until the end of NAC before surgery (ADC ratios 2–4). The thresholds to differentiate between cPR and pPR of ADC ratios 2, 3, and 4, were 1.14 × 10 −3 mm 2 /s, 1.08 × 10 −3 mm 2 /s, and 1.25 × 10 −3 mm 2 /s, respectively, and have a cross-validated sensitivity and specificity of 79.2%, 79.7% (ADC ratio 2); 100%, 66.7% (ADC ratio 3); and 100%, 83.8% (ADC ratio 4), respectively.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The ADC ratios were useful to differentiate cPR from pPR in breast cancer tumors after NAC. Thus, it may be useful in tailoring treatment in these patients.</p><h2 id="introduction"><span class="mr-2">Introduction</span><a href="#introduction" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Neoadjuvant chemotherapy (NAC), also known as primary or preoperatory chemotherapy, is used before surgical treatment. NAC is generally used as a part of conventional treatment in patients with locally advanced breast cancer with the potential to convert unresectable tumors into resectable tumors, to increase the possibility of breast conserving surgery, and also to provide an early management of micro-metastatic disease . In breast cancer, the survival benefit of patients receiving NAC is similar to that observed in patients who receive chemotherapy after surgery. Furthermore, the complete pathological response (cPR) or the absence of residual invasive disease in NAC is considered a favorable long-term predictive indicator or surrogate for survival . Even the measurement of tumor response in vivo to NAC may change the type and number of cycles of proposed chemotherapy .</p><p>The development of new anticancer therapies has prompted the search for new tools to assess the response to these therapies . The reference standard for evaluating the effects of new drugs is direct assessment of tumor tissue samples obtained through invasive techniques . In phase 2 and 3 clinical trials, the evaluation of the response to treatment is mainly measured in an indirect and less invasive manner using biological markers .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patients"><span class="mr-2">Patients</span><a href="#patients" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="breast-tumor-marking"><span class="mr-2">Breast Tumor Marking</span><a href="#breast-tumor-marking" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="chemotherapy-regimens"><span class="mr-2">Chemotherapy Regimens</span><a href="#chemotherapy-regimens" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="mri-acquisition"><span class="mr-2">MRI Acquisition</span><a href="#mri-acquisition" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-postprocessing"><span class="mr-2">Image Postprocessing</span><a href="#image-postprocessing" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/0_1s20S1076633217303677.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/0_1s20S1076633217303677.jpg" alt="Figure 1, Images of a 49-year-old woman. (a) Magnification of axial DWI before NAC, showing a mass in the union of upper quadrants of the left breast. (b) Magnification of axial DWI after the second cycle of NAC, showing the same mass. (c) Magnification of axial DWI before surgery, showing the same mass. (d) Magnification of axial ADC map before NAC at the same level as in (a) shows one of the three ROIs into the mass with an ADC value of 1.36 × 10 −3 mm 2s. (e) Magnification of axial ADC map after the second cycle of NAC at the same level as in (b) shows one of the three ROIs into the mass with an ADC value of 1.32 × 10 −3 mm 2s. Based on the average of the three ROIs, resulting in an ADC ratio 2 of 1.05 × 10 −3 mm 2s. (f) Magnification of axial ADC map before surgery at the same level as in (c) shows one of the three ROIs into the mass with an ADC value of 1.66 × 10 −3 mm 2s. Based on the average of the three ROIs, resulting in an ADC ratio 4 of 1.25 × 10 −3 mm 2s. The pathological result was infiltrating ductal carcinoma poorly differentiated, classified as triple negative by its immunohistochemical expression. In accordance to the Miller-Payne system, the surgical specimen had a grade 4 with a loss &gt;90% of the neoplastic cells, corresponding to pPR. ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; NAC, neoadjuvant chemotherapy; pPR, partial pathological response; ROIs, regions of interest." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/1_1s20S1076633217303677.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/1_1s20S1076633217303677.jpg" alt="Figure 2, Images of a 65-year-old woman. (a) Magnification of axial DWI before NAC, showing a mass in the union of outer quadrants of the right breast. (b) Magnification of axial DWI after the second cycle of NAC, showing the same mass. (c) Magnification of axial DWI before surgery, showing the same mass. (d) Magnification of axial ADC map before NAC at the same level as in (a) shows one of the three ROIs into the mass with an ADC value of 1.07 × 10 −3 mm 2s. (e) Magnification of axial ADC map after the second cycle of NAC at the same level as in (b) shows one of the three ROIs into the mass with an ADC value of 1.66 × 10 −3 mm 2s. Based on the average of the three ROIs, resulting in an ADC ratio 2 of 1.17 × 10 −3 mm 2s. (f) Magnification of axial ADC map before surgery at the same level as in (c) shows one of the three ROIs into the mass with an ADC value of 1.92 × 10 −3 mm 2s. Based on the average of the three ROIs, resulting in an ADC ratio 4 of 1.36 × 10 −3 mm 2s. The pathologic result was infiltrating ductal carcinoma moderately differentiated, classified as Her/2neu by its immunohistochemical expression. In accordance to the Miller-Payne system, the surgical specimen had a grade 5 with no malignant cells identifiable, corresponding to cPR, also was reported a fibrosis area of 4 cm. ADC, apparent diffusion coefficient; cPR, complete pathological response; DWI, diffusion-weighted imaging; NAC, neoadjuvant chemotherapy; ROIs, regions of interest." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="assessment-of-tumor-response"><span class="mr-2">Assessment of Tumor Response</span><a href="#assessment-of-tumor-response" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="data-collection"><span class="mr-2">Data Collection</span><a href="#data-collection" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 1</p><p>Clinicopathological Characteristics of the Population</p><p>Characteristic Breast Cancer Cases n = 16</p><p>Mean ± SD or n (%) cPR n = 4</p><p>Mean (SD) or n (%) pPR n = 12</p><p>Mean (SD) or n (%)<em>P</em> Values Age, years mean (SD) 48.5 (7.8) 51.5 (10.3) 47.5 (7.0) .39 Tumor grade, n (%) .99 Grade 2 (moderately differentiated) 11 (68.8) 3 (75) 8 (66.7) Grade 3 (poorly differentiated) 5 (31.3) 1 (25) 4 (33.3) Immunohistochemical expressions of ER, PR, and Her2/neu receptors, n (%) .40 Positive hormonal receptor 7 (43.8) 1 (25) 6 (50) Triple negative 5 (31.3) 1 (25) 4 (33.3) Her2/neu overexpressing 4 (25) 2 (50) 2 (16.7) Ki-67 protein status, n (%) .53 Low proliferation (&lt;20%) 13 (81.3) 4 (100) 9 (75) High proliferation (≥20%) 3 (18.8) 0 (0) 3 (25) MRI tumor size at diagnosis, mm mean (SD) 36.6 (17.6) 41.2 (29.5) 35.1 (13.1) .56 MRI tumor size at diagnosis, n (%) .59 &lt;20 mm 2 (12.5) 1 (25) 1 (8.3) 20–50 mm 11 (68.8) 2 (50) 9 (75) &gt;50 mm 3 (18.8) 1 (25) 2 (16.7) MRI tumor volume at diagnosis, cm 3 mean (SD) 15.9 (16.7) 18.7 (27.5) 15 (13.1) .71 MRI tumor size after second cycle NAC, mm mean (SD) 30 (16.6) 35.5 (27.4) 28.2 (12.5) .64 MRI tumor size after second cycle NAC, n (%) .09 &lt;20 mm 5 (31.3) 2 (50) 3 (25) 20–50 mm 10 (62.5) 1 (25) 9 (75) &gt;50 mm 1 (6.3) 1 (25) 0 (0) MRI tumor volume after second cycle NAC, cm 3 mean (SD) 10.3 (14) 12.8 (19.1) 9.4 (12.8) .69 MRI tumor size after NAC, mm mean (SD) 24.9 (15.9) 32.2 (25.5) 22.4 (11.8) .50 MRI tumor size after NAC, n (%) .16 &lt;20 mm 7 (43.8) 2 (50) 5 (41.7) 20–50 mm 8 (50) 1 (25) 7 (58.3) &gt;50 mm 1 (6.3) 1 (25) 0 (0) MRI tumor volume after NAC, cm 3 mean (SD) 3.36 (3.3) 3.18 (3.6) 3.43 (3.4) .90 Surgical specimen tumor size, mm mean (SD) 16.47 (14.6) 0 (0) 21.9 (12.7) .004 Tumor pathological response Miller-Payne, n (%) .001 Grade 1 (no reduction in overall cellularity) 2 (12.5) 0 (0) 2 (16.7) Grade 3 (30%–90% reduction in tumor cells) 6 (37.5) 0 (0) 6 (50) Grade 4 (&gt;90% loss of tumor cells) 4 (25) 0 (0) 4 (33.3) Grade 5 (no malignant cells identifiable) 4 (25) 4 (100) 0 (0)</p><p>cPR, complete pathological response; ER, estrogen receptor; MRI, magnetic resonance imaging; NAC, neoadjuvant chemotherapy; pPR, partial pathological response; PR, progesterone receptor; SD, standard deviation.</p><p><em>P</em> values calculated by Pearson χ 2 test or Fisher exact test for categorical variables and independent Student <em>t</em> test for numerical variables.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="measures-of-the-adc-ratios"><span class="mr-2">Measures of the ADC Ratios</span><a href="#measures-of-the-adc-ratios" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 2</p><p>Comparison Chart Between Mean ADC Ratios of cPR and pPR</p><p>ADC Ratios cPR n = 4</p><p>Mean ± SD pPR n = 12</p><p>Mean ± SD_P_ Values ADC ratio 1 1.08 ± 0.04 1.12 ± 0.09 .44 ADC ratio 2 1.30 ± 0.28 1.10 ± 0.10 .25 ADC ratio 3 1.35 ± 0.28 1.10 ± 0.15 .17 ADC ratio 4 1.49 ± 0.20 1.13 ± 0.21 .01</p><p>ADC, apparent diffusion coefficient; cPR, complete pathological response; pPR, partial pathological response; SD, standard deviation.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/2_1s20S1076633217303677.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/2_1s20S1076633217303677.jpg" alt="Figure 3, Box and whisker plot. Box and whisker plot shows the distribution of ADC ratio 4 for cPR and pPR. The median for cPR was 1.47 and for pPR was 1.20, and the minimum and maximum values were 1.29–1.73 for cPR and 0.62–1.43 for pPR. ADC, apparent diffusion coefficient; cPR, complete pathological response; pPR, partial pathological response." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="cross-validated-analysis"><span class="mr-2">Cross-validated Analysis</span><a href="#cross-validated-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 3</p><p>Cross-validated Threshold, Sensitivity, Specificity, and AUC</p><p>ADC Ratios Threshold (× 10 −3 mm 2 /s) Sensitivity (%) Specificity (%) AUC_P_ Values ADC ratio 1 ≤1.09 85.9 58.6 0.641 .34 ADC ratio 2 &gt;1.14 79.2 79.7 0.807 .03 ADC ratio 3 &gt;1.08 100 66.7 0.826 .01 ADC ratio 4 &gt;1.25 100 83.8 0.938 .0001</p><p>ADC, apparent diffusion coefficient; AUC, area under the curve.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/3_1s20S1076633217303677.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ApparentDiffusionCoefficientValuetoEvaluateTumorResponseAfterNeoadjuvantChemotherapyinPatientswithBreastCancer/3_1s20S1076633217303677.jpg" alt="Figure 4, ROC curve. ROC curve shows the diagnostic performance of all ADC ratios. The cross-validated AUC was significant at ADC ratios 2, 3, and 4. ADC, apparent diffusion coefficient; AUC, area under the curve; ROC, receiver operating characteristic curve." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="acknowledgments"><span class="mr-2">Acknowledgments</span><a href="#acknowledgments" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Boughey J.C., Peintinger F., Meric-Bernstam F., et. al.: Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 2006; 244: pp. 464-470.</p><li><p>2. Ogston K.N., Miller I.D., Payne S., et. al.: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003; 9776: pp. 320-327.</p><li><p>3. Lobbes M., Prevos R., Smidt M.: Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using breast MRI—a review of current knowledge. J Cancer Ther Res 2012;</p><li><p>4. Sawyers C.L.: The cancer biomarker problem. Nature 2008; 452: pp. 548-552.</p><li><p>5. Tan D.S.W., Thomas G.V., Garrett M.D., et. al.: Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009; 15: pp. 406-420.</p><li><p>6. Van Beers B.E., Vilgrain V.: Biomarkers in abdominal imaging. Abdom Imaging 2009; 34: pp. 663-667.</p><li><p>7. Rezai P., Pisaneschi M.J., Feng C., et. al.: A radiologist’s guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers. Am J Roentgenol 2013; 201: pp. 237-245.</p><li><p>8. Sadeghi-Naini A., Vorauer E., Chin L., et. al.: Early detection of chemotherapy-refractory patients by monitoring textural alterations in diffuse optical spectroscopic images. Med Phys 2015; 42: pp. 6130-6146.</p><li><p>9. Sadeghi-Naini A., Papanicolau N., Falou O., et. al.: Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients receiving chemotherapy. Clin Cancer Res 2013; 19: pp. 2163-2175.</p><li><p>10. Falou O., Sadeghi-Naini A., Prematilake S., et. al.: Evaluation of neoadjuvant chemotherapy response in women with locally advanced breast cancer using ultrasound elastography. Transl Oncol 2013; 6: pp. 17-24.</p><li><p>11. Pio B.S., Park C.K., Pietras R., et. al.: Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy. Mol Imaging Biol 2006; 8: pp. 36-42.</p><li><p>12. Chou C.-P., Wu M.-T., Chang H.-T., et. al.: Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol 2007; 14: pp. 561-573.</p><li><p>13. Ahmed A., Gibbs P., Pickles M., et. al.: Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging 2013; 101: pp. 89-101.</p><li><p>14. Cheung Y.C., Chen S.C., Su M.Y., et. al.: Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003; 78: pp. 51-58.</p><li><p>15. Rieber A., Brambs H.J., Gabelmann A., et. al.: Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 2002; 12: pp. 1711-1719.</p><li><p>16. Gilles R., Guinebreti J., Toussaint C., et. al.: Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191: pp. 633-638.</p><li><p>17. Witney T., Kettunen M., Hu D., et. al.: Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1–13 C] pyruvate and [1,4–13 C2] fumarate. Br J Cancer 2010; 103: pp. 1400-1406.</p><li><p>18. Jagannathan N.R., Kumar M., Seenu V., et. al.: Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001; 84: pp. 1016-1022. May 1999</p><li><p>19. Tardivon A.A., Ollivier L., El Khoury C., et. al.: Monitoring therapeutic efficacy in breast carcinomas. Eur Radiol 2006; 16: pp. 2549-2558.</p><li><p>20. Larkin T.J., Canuto H.C., Kettunen M.I., et. al.: Analysis of image heterogeneity using 2D Minkowski functionals detects tumor responses to treatment. Magn Reson Med 2014; 410: pp. 402-410.</p><li><p>21. Pickles M.D., Gibbs P., Lowry M., et. al.: Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: pp. 843-847.</p><li><p>22. Sharma U., Kalathil K., Danishad A., et. al.: Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22: pp. 104-113.</p><li><p>23. Gutiérrez-Sánchez J.B., Montemayor-Martínez A., Ornelas-Cortinas G., et. al.: Caso clínico Utilidad del carbón activado en el marcaje de mama. Med Univ 2009; 11: pp. 55-59.</p><li><p>24. Grimm L.J., Breast M.R.I.: Radiogenomics: current status and research implications. J Magn Reson Imaging 2016; 43: pp. 1269-1278.</p><li><p>25. Liu S., Ren R., Chen Z., et. al.: Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy. J Magn Reson Imaging 2015; 42: pp. 779-787.</p><li><p>26. Masuda N., Lee S.J., Ohtani S., et. al.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: pp. 2147-2159.</p><li><p>27. Teshome M., Kuerer H.M.: Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. EJSO 2017; 43: pp. 865-874.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-25/'>Volume 25</a>, <a href='/categories/issue-2/'>Issue 2</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Apparent%20Diffusion%20Coefficient%20Value%20to%20Evaluate%20Tumor%20Response%20After%20Neoadjuvant%20Chemotherapy%20in%20Patients%20with%20Breast%20Cancer%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fapparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Apparent%20Diffusion%20Coefficient%20Value%20to%20Evaluate%20Tumor%20Response%20After%20Neoadjuvant%20Chemotherapy%20in%20Patients%20with%20Breast%20Cancer%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fapparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fapparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa%2F&text=Apparent%20Diffusion%20Coefficient%20Value%20to%20Evaluate%20Tumor%20Response%20After%20Neoadjuvant%20Chemotherapy%20in%20Patients%20with%20Breast%20Cancer%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/accuracy-of-computed-tomographic-enterography-for-obscure-gastrointestinal-bleeding/"><div class="card-body"> <em class="small" data-ts="1517418000" data-df="ll" > Jan 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Accuracy of Computed Tomographic Enterography for Obscure Gastrointestinal Bleeding</h3><div class="text-muted small"><p> Rationale and Objectives Obscure gastrointestinal bleeding (OGIB) is the bleeding from the gastrointestinal tract without definite source that persists and recurs after a negative endoscopic evalu...</p></div></div></a></div><div class="card"> <a href="/posts/automated-radiology-operative-note-communication-tool-closing-the-loop-in-musculoskeletal-imaging/"><div class="card-body"> <em class="small" data-ts="1517418000" data-df="ll" > Jan 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Radiology-Operative Note Communication Tool; Closing the Loop in Musculoskeletal Imaging</h3><div class="text-muted small"><p> Rationale and Objectives Correlation of imaging studies and reference standard outcomes is a significant challenge in radiology. This study evaluates the effectiveness of a new communication tool ...</p></div></div></a></div><div class="card"> <a href="/posts/can-radiologists-learn-from-airport-baggage-screening/"><div class="card-body"> <em class="small" data-ts="1517418000" data-df="ll" > Jan 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Can Radiologists Learn From Airport Baggage Screening?</h3><div class="text-muted small"><p> Rationale and Objectives For both airport baggage screeners and radiologists, low target prevalence is associated with low detection rate, a phenomenon known as “prevalence effect.” In airport bag...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/accuracy-of-computed-tomographic-enterography-for-obscure-gastrointestinal-bleeding/" class="btn btn-outline-primary" prompt="Older"><p>Accuracy of Computed Tomographic Enterography for Obscure Gastrointestinal Bleeding</p></a> <a href="/posts/automated-radiology-operative-note-communication-tool-closing-the-loop-in-musculoskeletal-imaging/" class="btn btn-outline-primary" prompt="Newer"><p>Automated Radiology-Operative Note Communication Tool; Closing the Loop in Musculoskeletal Imaging</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
